Analyzing Stem Cell Functionality in Obese Patients

Overview

About this study

The purpose of this study is to advance knowledge in human stem cell functionality for obesity to develop a novel therapeutic strategy to improve endogenous reparative systems.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

All subjects eligible for this study will meet the following inclusion criteria:

  • Age 18-80 years;
  • BMI ≥30 kg/m2;
  • Ability to provide consent.

Exclusion Criteria: 

Subjects will be excluded from participation if they have any of the following exclusion criteria:

  • Pregnancy;
  • Chronic Inflammatory Disease (e.g. rheumatoid arthritis);
  • Active malignancy;
  • Recent stroke or myocardial infarction;
  • Solid organ transplant recipients;
  • Therapeutic doses of immunosuppressive drugs (including calcineurin inhibitors and prednisone (>10 mg/day);
  • Senolytic supplements;
  • Subjects on therapeutic doses of anticoagulants [including Warfarin (Coumadin), Rivaroxaban (Xarleto); Apixaban (Eliquis); Dabigatran (Pradaxa, Prazaxa)];
  • Subjects deemed ineligible to comply with study protocol.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lilach Lerman, M.D., Ph.D.

Closed for enrollment

Contact information:

Department of Medicine – Clinical Trials Unit

(507) 266-1944

RSTDOMCTU@mayo.edu

More information

Publications

Publications are currently not available